Valuation, page-14

Hi @stokdog,

re your observation " Large players could offer a deal that is too good to refuse for the PLATFORM",

it begs the question: What would be a deal 'too good to refuse' for a platform - say Remestemcel-l - which has:

- ownership of its own IP, including first-in-class patent protection to defend itself in all significant global markets
- passed all phases of research & then clinical development up to Ph IV,
- a massive use database second to none in the cell therapy industry,
- a first-in-class FDA approval in the largest & most persuasive market in the world,
- reference pricing agreed with payers,
- a funded clinical trial in the USA,
- demonstrated commercial manufacturing capability of its protocols,
- a PLI with zero 483s, &
- critically has label expansion indications queueing up with Accelerated Approval pathway endorsement from the hardest regulator etc etc

Talk about emerging value. How about EMERGING VALUE!!!!.

Honestly, I can't think of a number now that could possibly bring any reasoned analysis to this calculation & that didn't end up in completely speculative multiple tens of billions of US dollars. And, as far as a number later goes, forget it.

Cheers
GLTA(LT)H